Connect with our researchers, identify collaborators, discover their work
Clinical outcomes and survival following lung transplantation in patients with lymphangioleiomyomatosis. Journal Article
Local Library Link: Find It @ Loyola
| Authors: | Khawar, MU; Yazdani, D; Zhu, Z; Jandarov, R; Dilling, DF; Gupta, N |
| Article Title: | Clinical outcomes and survival following lung transplantation in patients with lymphangioleiomyomatosis. |
| Abstract: | BACKGROUND: The primary aim of our study was to derive disease-specific outcomes following lung transplantation (LT) in patients with lymphangioleiomyomatosis (LAM). METHODS: We queried the Organ Procurement and Transplant Network database to identify LAM patients that have undergone LT in the United States. The overall survival was analyzed with Kaplan-Meier curves. Survival estimates between subgroups of interest were compared using the log-rank method. Cox proportional hazard models were employed to determine the pre-transplant variables that impact post-LT survival. RESULTS: One hundred and thirty-eight women with LAM underwent LT at 31 centers between January 2003 and June 2017. The median age at listing and transplant was 44 (IQR: 36-51) and 45 (IQR: 38-52) years, respectively. The median time spent on the LT waitlist was 257 (IQR: 85-616) days. The majority of the patients (109/134, 81%) received bilateral sequential LT. The median ischemic time was 4.9 (IQR: 4.1-6.1) hours. The actuarial Kaplan-Meier survival following LT for LAM patients at 1-, 5-, and 10 years was 94%, 73% and 56%, respectively. The post-LT survival was significantly better in LAM than in other lung diseases (10-year survival 56% vs. 32%, p 0.01), and this advantage persisted after age- and gender-matched analysis (10-year survival 54% vs. 37%, p 0.01). Pre-transplant parameters, such as the presence of pulmonary hypertension, six-minute walk distance, age at transplant, ischemic time during transplant, or type of transplant (single vs bilateral sequential LT), did not affect post-transplant survival. CONCLUSIONS: The median survival after LT in LAM is 12 years and is substantially better than in other lung diseases. |
| Journal Title: | The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation |
| ISSN: | 1557-3117; 1053-2498 |
| Publisher: | Unknown |
| Date Published: | 2019 |
